Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Placebo Controlled Dose Ranging Study to Assess the Effect of RPL554 Added on to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease

Next Previous
Trial Profile

A Phase II, Randomized, Double-Blind, Placebo Controlled Dose Ranging Study to Assess the Effect of RPL554 Added on to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ensifentrine (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Verona Pharma

Most Recent Events

  • 19 May 2021 Results (n=413) assessing the gastrointestinal and cardiovascular-related adverse events reported from a four-week, presented at the 117th International Conference of the American Thoracic Society.
  • 19 May 2021 Results of sub-group analysis (n=413) assessing the effect of ensifentrine on lung function and health-related quality of life (QoL) by COPD Severity, presented at the 117th International Conference of the American Thoracic Society.
  • 19 May 2021 Results from two, Phase 2b studies NCT03443414 (n=403) and NCT03937479 (n=413) assessing the efficacy and safety of multiple doses of nebulized ensifentrine in patients with moderate-severe chronic obstructive pulmonary disease, presented at the 117th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top